Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.

Clinical case definition Influenza Influenza vaccine Multicenter study Test-negative design Vaccine effectiveness

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
03 May 2024
Historique:
received: 05 12 2023
revised: 03 04 2024
accepted: 21 04 2024
medline: 5 5 2024
pubmed: 5 5 2024
entrez: 4 5 2024
Statut: aheadofprint

Résumé

Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS primary care European multicentre study end-of-season data to evaluate whether the clinical case definition affected IVE estimates. We estimated VE using a multicentre test-negative case-control design. We measured VE against any influenza and influenza (sub)types, by age group (0-14, 15-64, ≥65 years) and by influenza vaccine target group, using logistic regression. We estimated IVE among patients meeting the European Union (EU) acute respiratory infection (ARI) case definition and among those meeting the EU influenza-like illness (ILI) case definition, including only sites providing information on specific symptoms and recruiting patients using an ARI case definition (as the EU ILI case definition is a subset of the EU ARI one). We included 24 319 patients meeting the EU ARI case definition, of whom 21 804 patients (90 %) meet the EU ILI case definition, for the overall pooled VE analysis against any influenza. The overall and influenza (sub)type-specific VE varied by ≤2 % between EU ILI and EU ARI populations. Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022-23 influenza season was not affected by use of a different clinical case definition for recruitment, although we recommend investigating whether this holds true for next seasons.

Sections du résumé

BACKGROUND BACKGROUND
Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS primary care European multicentre study end-of-season data to evaluate whether the clinical case definition affected IVE estimates.
METHODS METHODS
We estimated VE using a multicentre test-negative case-control design. We measured VE against any influenza and influenza (sub)types, by age group (0-14, 15-64, ≥65 years) and by influenza vaccine target group, using logistic regression. We estimated IVE among patients meeting the European Union (EU) acute respiratory infection (ARI) case definition and among those meeting the EU influenza-like illness (ILI) case definition, including only sites providing information on specific symptoms and recruiting patients using an ARI case definition (as the EU ILI case definition is a subset of the EU ARI one).
RESULTS RESULTS
We included 24 319 patients meeting the EU ARI case definition, of whom 21 804 patients (90 %) meet the EU ILI case definition, for the overall pooled VE analysis against any influenza. The overall and influenza (sub)type-specific VE varied by ≤2 % between EU ILI and EU ARI populations.
DISCUSSION CONCLUSIONS
Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022-23 influenza season was not affected by use of a different clinical case definition for recruitment, although we recommend investigating whether this holds true for next seasons.

Identifiants

pubmed: 38704257
pii: S0264-410X(24)00497-3
doi: 10.1016/j.vaccine.2024.04.060
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Marine Maurel (M)

Epiconcept, Paris, France.

Clara Mazagatos (C)

National Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain.

Luise Goerlitz (L)

Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.

Beatrix Oroszi (B)

National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.

Mariette Hooiveld (M)

Nivel, Utrecht, the Netherlands.

Ausenda Machado (A)

Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.

Lisa Domegan (L)

HSE-Health Protection Surveillance Centre, Dublin, Ireland.

Maja Ilić (M)

Croatian Institue of Public Health, Zagreb, Croatia.

Rodica Popescu (R)

National Institute of Public Health, Bucharest, Romania.

Noémie Sève (N)

Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.

Iván Martínez-Baz (I)

Instituto de Salud Pública - IdiSNA- CIBERESP, Pamplona, Spain.

Amparo Larrauri (A)

National Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain.

Silke Buda (S)

Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.

Gergő Túri (G)

National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.

Adam Meijer (A)

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Verónica Gomez (V)

Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.

Joan O'Donnell (J)

HSE-Health Protection Surveillance Centre, Dublin, Ireland.

Ivan Mlinarić (I)

Croatian Institue of Public Health, Zagreb, Croatia.

Olivia Timnea (O)

"Cantacuzino" National Military Medical Institute for Research and Development, Bucharest, Romania.

Ana Ordax Diez (AO)

Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL). Consejería de Sanidad. Junta de Castilla y León, Valladolid, Spain.

Ralf Dürrwald (R)

National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.

Judit Krisztina Horváth (JK)

National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.

Frederika Dijkstra (F)

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Ana Paula Rodrigues (AP)

Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.

Adele McKenna (A)

HSE-Health Protection Surveillance Centre, Dublin, Ireland.

Sanja Kurečić Filipović (SK)

Croatian Institue of Public Health, Zagreb, Croatia.

Mihaela Lazar (M)

"Cantacuzino" National Military Medical Institute for Research and Development, Bucharest, Romania.

Marlena Kaczmarek (M)

European Centre for Disease Prevention and Control, Stockholm, Sweden.

Sabrina Bacci (S)

European Centre for Disease Prevention and Control, Stockholm, Sweden.

Esther Kissling (E)

Epiconcept, Paris, France.

Classifications MeSH